IP Library Granted Patent US 12,357,209
Granted Patent B2
US 12,357,209 · App. 18/494,622 · Granted Jul 15, 2025

Blood sample optimization device

Inventors: Bobby E. Rogers (Park City, UT); Gino Kang (Irvine, CA); John Detloff (San Diego, CA)
Assignee: Kurin, Inc.
A61B5/150992A61B5/15003A61B5/150213A61B5/150221A61B5/150389A61B5/150473A61B5/150572A61B5/153A61B5/154A61M39/04A61M39/0693A61M2039/0202A61M2039/0633A61M2039/068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,209
App. No.
18/494,622
Granted
Jul 15, 2025
Kind
B2
Abstract

Blood sample optimization systems and methods are described that reduce or eliminate contaminates in collected blood samples, which in turn reduces or eliminates false positive readings in blood cultures or other testing of collected blood samples. A blood sample optimization system can include a blood sequestration device located between a patient needle and a sample needle. The blood sequestration device can include a sequestration chamber for sequestering an initial, potentially contaminated aliquot of blood, and may further include a sampling channel that bypasses the sequestration chamber to convey likely uncontaminated blood between the patient needle and the sample needle after the initial aliquot of blood is sequestered in the sequestration chamber.

Claims (43)

1. A device comprising:

an inlet port configured for receiving a blood sample;

an outlet port;

a chamber connected to the inlet port and being configured to collect a first portion of the blood sample, the chamber having a blood impermeable membrane configured to facilitate the chamber collecting the first portion of the blood sample;

a housing, separate from the blood impermeable membrane; and

a sampling channel connected with the inlet port and configured to convey a subsequent portion of the blood sample to the outlet port.

2. The device in accordance with claim 1 , wherein the blood impermeable membrane is configured to cause the first portion of the blood sample to back up into the chamber following application of a drawing force applied from the outlet port.

3. The device in accordance with claim 1 , wherein the device is configured such that, when a drawing force is applied at the outlet port, the first portion of the blood sample is drawn into the chamber to contact a material that is blood impermeable.

4. The device in accordance with claim 1 , further comprising a valve configured to initially close off the sampling channel.

5. The device in accordance with claim 1 , further comprising a valve configured to initially close off the sampling channel until the first portion of the blood sample is in the chamber.

6. The device in accordance with claim 1 , further comprising a valve that is configured to initially close off the sampling channel until the first portion of the blood sample is in the chamber and is further configured such that, upon release, the subsequent portion of the blood sample will bypass the chamber and flow through the sampling channel toward the outlet port.

7. The device in accordance with claim 4 , wherein the valve is configured to pinch, shunt, bend or otherwise close off the sampling channel before the first portion of the blood sample is collected in the chamber.

8. The device in accordance with claim 1 , wherein the housing defines the inlet port, the sampling channel, and the outlet port.

9. The device in accordance with claim 1 , further comprising a patient needle and a sample collection device.

10. The device in accordance with claim 1 , the chamber having a volume configured to be sufficient to collect the first portion of the blood sample that is more prone to contamination and also to minimize an amount of blood to be sequestered.

11. The device in accordance with claim 1 , wherein the chamber has a volume of less than 1.5 cubic centimeters.

12. A device comprising:

an inlet port configured for receiving blood;

an outlet port;

a chamber connected to the inlet port and being configured to collect a first portion of the blood, the chamber comprising a flexible blood impermeable membrane that allows the chamber to collect the first portion of the blood; and

a sampling channel connected with the inlet port and configured to convey a subsequent portion of the blood to the outlet port.

13. The device in accordance with claim 12 , wherein the flexible blood impermeable membrane is configured to cause the first portion of the blood to back up into the chamber following application of a drawing force applied from the outlet port.

14. The device in accordance with claim 12 , wherein the device is configured such that, when a drawing force is applied at the outlet port, the first portion of the blood is drawn into the chamber to contact a material that is blood impermeable.

15. The device in accordance with claim 12 , further comprising a valve configured to initially close off the sampling channel.

16. The device in accordance with claim 12 , further comprising a valve configured to initially close off the sampling channel until the first portion of the blood is in the chamber.

17. The device in accordance with claim 12 , further comprising a valve that is configured to initially close off the sampling channel until the first portion of the blood is in the chamber and is further configured such that, upon release, the subsequent portion of the blood will bypass the chamber and flow through the sampling channel toward the outlet port.

18. The device in accordance with claim 15 , wherein the valve is configured to pinch, shunt, bend or otherwise close off the sampling channel before the first portion of the blood is collected in the chamber.

19. The device in accordance with claim 12 , further comprising a patient needle and a sample collection device.

20. The device in accordance with claim 12 , the chamber having a volume configured to be sufficient to collect the first portion of the blood that is more prone to contamination and also to minimize an amount of blood to be sequestered.

21. A device comprising:

an inlet port configured for receiving blood;

an outlet port;

a chamber connected to the inlet port, the chamber having a blood impermeable membrane and being configured to collect a first portion of the blood; and

a sampling channel connected with the inlet port and configured to convey a subsequent portion of the blood to the outlet port.

22. The device in accordance with claim 21 , wherein the blood impermeable membrane is configured to cause the first portion of the blood to back up into the chamber following application of a drawing force applied from the outlet port.

23. The device in accordance with claim 21 , wherein the device is configured such that, when a drawing force is applied at the outlet port, the first portion of the blood is drawn into the chamber to contact a material that is blood impermeable.

24. The device in accordance with claim 21 , further comprising a valve configured to initially close off the sampling channel.

25. The device in accordance with claim 21 , further comprising a valve configured to initially close off the sampling channel until the first portion of the blood is in the chamber.

26. The device in accordance with claim 21 , further comprising a valve that is configured to initially close off the sampling channel until the first portion of the blood is in the chamber and is further configured such that, upon release, the subsequent portion of the blood will bypass the chamber and flow through the sampling channel toward the outlet port.

27. The device in accordance with claim 24 , wherein the valve is configured to pinch, shunt, bend or otherwise close off the sampling channel before the first portion of the blood is collected in the chamber.

28. The device in accordance with claim 21 , further comprising a patient needle and a sample collection device.

29. The device in accordance with claim 21 , the chamber having a volume configured to be sufficient to collect the first portion of the blood that is more prone to contamination and also to minimize an amount of blood to be sequestered.

30. The device in accordance with claim 21 , wherein the chamber has a volume of less than 1.5 cubic centimeters.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2024
From: ROGERS, BOBBY E.; KANG, GINO; DETLOFF, JOHN
To: KURIN, INC.
Reel/Frame 066877/0695 →
Continuity (9)
Continuation 18113710 · Feb 24, 2023
Continuation 17538990 · Nov 30, 2021
Continuation 16208559 · Dec 4, 2018
Continuation 15994559 · May 31, 2018
Continuation 15140448 · Apr 27, 2016
Provisional Application 62318194 · Apr 4, 2016
Provisional Application 62238636 · Oct 7, 2015
Provisional Application 62196797 · Jul 24, 2015
Related Publication 20240252079A1 · Aug 1, 2024
References Cited (370)
US 3382865A · Worrall, Jr. · 1968 [cited by applicant]
US 3494352A · Russo · 1970 [cited by applicant]
US 3604410A · Whitacre · 1971 [cited by applicant]
US 3648684A · Barnwell · 1972 [cited by applicant]
US 3741197A · Sanz · 1973 [cited by examiner]
US 3817240A · Ayres · 1974 [cited by examiner]
US 3835835A · Thompson · 1974 [cited by applicant]
US 3848579A · Villa · 1974 [cited by applicant]
US 3848581A · Cinqualbre · 1974 [cited by applicant]
US 3859998A · Thomas · 1975 [cited by applicant]
US 3874367A · Ayres · 1975 [cited by examiner]
US 3886930A · Ryan · 1975 [cited by examiner]
US 3945380A · Dabney · 1976 [cited by applicant]
US 4056101A · Geissler · 1977 [cited by applicant]
US 4057050A · Sarstedt · 1977 [cited by examiner]
US 4106497A · Percarpio · 1978 [cited by examiner]
US 4150089A · Linet · 1979 [cited by applicant]
US 4154229A · Nugent · 1979 [cited by examiner]
US 4193400A · Loveless · 1980 [cited by applicant]
US 4207870A · Eldridge · 1980 [cited by examiner]
US 4257416A · Prager · 1981 [cited by applicant]
US 4312362A · Kaufman · 1982 [cited by applicant]
US 4349035A · Thomas · 1982 [cited by applicant]
US 4373535A · Martell · 1983 [cited by applicant]
US 4412548A · Hoch · 1983 [cited by examiner]
US 4416290A · Lutkowski · 1983 [cited by applicant]
US 4416291A · Kaufman · 1983 [cited by applicant]
US 4436098A · Kaufman · 1984 [cited by examiner]
US 4444203A · Engelman · 1984 [cited by examiner]
US 4673386A · Gordon · 1987 [cited by applicant]
US 4690154A · Woodford · 1987 [cited by applicant]
US 4813433A · Downey · 1989 [cited by applicant]
US 4904240A · Hoover · 1990 [cited by applicant]
US 4980297A · Haynes · 1990 [cited by applicant]
US 5045185A · Ohnaka · 1991 [cited by applicant]
US 5097842A · Bonn · 1992 [cited by applicant]
US 5100394A · Dudar · 1992 [cited by applicant]
US 5135489A · Jepson · 1992 [cited by applicant]
US 5147329A · Brannon · 1992 [cited by applicant]
US 5200325A · Blatt · 1993 [cited by applicant]
US 5222502A · Kurose · 1993 [cited by examiner]
US 5401262A · Karwoski · 1995 [cited by applicant]
US 5417673A · Gordon · 1995 [cited by applicant]
US 5431811A · Tusini · 1995 [cited by applicant]
US 5432084A · Brubaker · 1995 [cited by applicant]
US 5439450A · Haedt · 1995 [cited by applicant]
US 5518005A · Brannon · 1996 [cited by applicant]
US 5520193A · Suzuki · 1996 [cited by examiner]
US 5632906A · Ishida · 1997 [cited by applicant]
US 5691486A · Behringer · 1997 [cited by applicant]
US 5749857A · Cuppy · 1998 [cited by examiner]
US 5772608A · Dhas · 1998 [cited by applicant]
US 5811658A · Van Driel · 1998 [cited by applicant]
US 5865803A · Major · 1999 [cited by applicant]
US 5873841A · Brannon · 1999 [cited by applicant]
US 5972294A · Smith · 1999 [cited by applicant]
US 5980830A · Savage · 1999 [cited by applicant]
US 6013037A · Brannon · 2000 [cited by applicant]
US 6106509A · Loubser · 2000 [cited by applicant]
US 6126643A · Vaillancouert · 2000 [cited by applicant]
US 6187347B1 · Patterson · 2001 [cited by applicant]
US 6224561B1 · Swendson · 2001 [cited by applicant]
US 6398743B1 · Halseth · 2002 [cited by examiner]
US 6506182B2 · Estabrook · 2003 [cited by applicant]
US 6569117B1 · Ziv · 2003 [cited by examiner]
US 6599474B2 · Evtodienko · 2003 [cited by applicant]
US 6626884B1 · Dillon · 2003 [cited by applicant]
US 6638252B2 · Moulton · 2003 [cited by applicant]
US 6695004B1 · Raybuck · 2004 [cited by applicant]
US 6733433B1 · Fell · 2004 [cited by applicant]
US 6736783B2 · Blake · 2004 [cited by applicant]
US 6843775B2 · Hyun · 2005 [cited by applicant]
US 6860871B2 · Kuracina · 2005 [cited by applicant]
US 6905483B2 · Newby · 2005 [cited by applicant]
US 6913580B2 · Stone · 2005 [cited by applicant]
US 6945948B2 · Bainbridge · 2005 [cited by applicant]
US 7052603B2 · Schick · 2006 [cited by applicant]
US 7055401B2 · Prybella · 2006 [cited by applicant]
US 7241281B2 · Coelho · 2007 [cited by applicant]
US 7306736B2 · Collins · 2007 [cited by applicant]
US 7461671B2 · Ehwald · 2008 [cited by applicant]
US 7479131B2 · Mathias · 2009 [cited by applicant]
US 7666166B1 · Emmert · 2010 [cited by applicant]
US 8070725B2 · Christensen · 2011 [cited by applicant]
US 8197420B2 · Patton · 2012 [cited by examiner]
US 8349254B2 · Hoshino · 2013 [cited by applicant]
US 8377040B2 · Burkholz · 2013 [cited by applicant]
US 8523826B2 · Layton, Jr. · 2013 [cited by examiner]
US 8535241B2 · Bullington · 2013 [cited by examiner]
US 8540663B2 · Davey · 2013 [cited by examiner]
US 8568371B2 · Siopes · 2013 [cited by examiner]
US 8574203B2 · Stout · 2013 [cited by applicant]
US 8603009B2 · Tan · 2013 [cited by examiner]
US 8827958B2 · Bierman · 2014 [cited by applicant]
US 8864684B2 · Bullington · 2014 [cited by examiner]
US 9022950B2 · Bullington · 2015 [cited by examiner]
US 9022951B2 · Bullington · 2015 [cited by examiner]
US 9060724B2 · Bullington · 2015 [cited by examiner]
US 9138572B2 · Zeytoonian · 2015 [cited by examiner]
US 9155495B2 · Bullington · 2015 [cited by examiner]
US 9204864B2 · Bullington · 2015 [cited by examiner]
US 9764891B1 · Aviles · 2017 [cited by applicant]
US 9820682B2 · Rogers · 2017 [cited by applicant]
US 9877675B2 · Baid · 2018 [cited by examiner]
US 10010282B2 · Rogers · 2018 [cited by applicant]
US 10143412B2 · Rogers · 2018 [cited by applicant]
US 10265007B2 · Bullington · 2019 [cited by applicant]
US 10299713B2 · Patton · 2019 [cited by applicant]
US 10596315B2 · Bullington · 2020 [cited by applicant]
US 10624977B2 · Bullington · 2020 [cited by applicant]
US 10827964B2 · Rogers · 2020 [cited by applicant]
US 10881343B2 · Bullington · 2021 [cited by applicant]
US 11185266B2 · Rogers · 2021 [cited by applicant]
US 11213232B2 · Ivosevic · 2022 [cited by applicant]
US 11234626B2 · Bullington · 2022 [cited by applicant]
US 11259727B2 · Bullington · 2022 [cited by applicant]
US 11311219B2 · Rogers · 2022 [cited by applicant]
US 11395612B2 · Bullington · 2022 [cited by applicant]
US 11419531B2 · Bullington · 2022 [cited by applicant]
US 11439332B2 · Bullington · 2022 [cited by applicant]
US 11589843B2 · Bullington · 2023 [cited by applicant]
US 11612340B2 · Bullington · 2023 [cited by applicant]
US 11653863B2 · Bullington · 2023 [cited by applicant]
US 11660030B2 · Bullington · 2023 [cited by applicant]
US 11737693B2 · Bullington · 2023 [cited by applicant]
US 11786155B2 · Bullington · 2023 [cited by applicant]
US 11789017B2 · Bullington · 2023 [cited by applicant]
US 20010044615A1 · Amano · 2001 [cited by applicant]
US 20020004647A1 · Leong · 2002 [cited by examiner]
US 20030082074A1 · Jurik · 2003 [cited by applicant]
US 20030105414A1 · Leong · 2003 [cited by examiner]
US 20030185707A1 · Iwaki · 2003 [cited by applicant]
US 20030208151A1 · Kraus · 2003 [cited by applicant]
US 20040054333A1 · Theeuwes · 2004 [cited by examiner]
US 20040073171A1 · Rogers · 2004 [cited by examiner]
US 20040112808A1 · Takagi · 2004 [cited by applicant]
US 20040116830A1 · Trudeau · 2004 [cited by applicant]
US 20040147855A1 · Marsden · 2004 [cited by examiner]
US 20050004524A1 · Newby · 2005 [cited by examiner]
US 20050005635A1 · Le Metais · 2005 [cited by applicant]
US 20050007524A1 · Luo · 2005 [cited by applicant]
US 20050161112A1 · Ehwald · 2005 [cited by applicant]
US 20050240161A1 · Crawford · 2005 [cited by examiner]
US 20050245885A1 · Brown · 2005 [cited by applicant]
US 20050273019A1 · Conway · 2005 [cited by applicant]
US 20060009713A1 · Flaherty · 2006 [cited by applicant]
US 20070031283A1 · Davis · 2007 [cited by applicant]
US 20070083162A1 · O'Reagan · 2007 [cited by examiner]
US 20070088279A1 · Shue · 2007 [cited by examiner]
US 20070119508A1 · West · 2007 [cited by applicant]
US 20080086085A1 · Brown · 2008 [cited by examiner]
US 20080145933A1 · Patton · 2008 [cited by examiner]
US 20080167577A1 · Weilbacher · 2008 [cited by examiner]
US 20080319346A1 · Crawford · 2008 [cited by examiner]
US 20090227953A1 · Tan · 2009 [cited by applicant]
US 20090299253A1 · Hursey · 2009 [cited by applicant]
US 20100010372A1 · Brown · 2010 [cited by examiner]
US 20100057004A1 · Christensen · 2010 [cited by examiner]
US 20110306899A1 · Brown · 2011 [cited by applicant]
US 20120016266A1 · Burkholz · 2012 [cited by examiner]
US 20130116599A1 · Bullington · 2013 [cited by applicant]
US 20130158506A1 · Harris · 2013 [cited by applicant]
US 20130317391A1 · Bullington · 2013 [cited by examiner]
US 20140039348A1 · Bullington · 2014 [cited by applicant]
US 20140073990A1 · Holmes · 2014 [cited by applicant]
US 20140107564A1 · Bullington · 2014 [cited by applicant]
US 20140112841A1 · Schoen · 2014 [cited by applicant]
US 20140155781A1 · Bullington · 2014 [cited by applicant]
US 20140155782A1 · Bullington · 2014 [cited by applicant]
US 20140163419A1 · Bullington · 2014 [cited by applicant]
US 20140276578A1 · Bullington · 2014 [cited by applicant]
US 20140309558A1 · Fletcher · 2014 [cited by applicant]
US 20140323911A1 · Sloan · 2014 [cited by applicant]
US 20150246352A1 · Bullington · 2015 [cited by applicant]
US 20150314105A1 · Gasparyan · 2015 [cited by applicant]
US 20150342510A1 · Bullington · 2015 [cited by applicant]
US 20150351678A1 · Bullington · 2015 [cited by applicant]
US 20150359473A1 · Garrett · 2015 [cited by applicant]
US 20160008579A1 · Burkholz · 2016 [cited by examiner]
US 20160017488A1 · Kobayashi · 2016 [cited by applicant]
US 20160073937A1 · Burkholz · 2016 [cited by applicant]
US 20160174888A1 · Berthier · 2016 [cited by examiner]
US 20160262677A1 · Ebetsberger · 2016 [cited by applicant]
US 20160325085A1 · Chelak · 2016 [cited by examiner]
US 20160361006A1 · Bullington · 2016 [cited by applicant]
US 20170020427A1 · Rogers · 2017 [cited by applicant]
US 20170020428A1 · Rogers · 2017 [cited by applicant]
US 20170065733A1 · Bullington · 2017 [cited by applicant]
US 20180140240A1 · Bullington · 2018 [cited by applicant]
US 20180177445A1 · Rogers · 2018 [cited by applicant]
US 20180271425A1 · Rogers · 2018 [cited by applicant]
US 20180297303A1 · Sekiguchi · 2018 [cited by applicant]
US 20180353117A1 · Bullington · 2018 [cited by applicant]
US 20190159711A1 · Rogers · 2019 [cited by applicant]
US 20190175087A1 · Bullington · 2019 [cited by applicant]
US 20190365303A1 · Bullington · 2019 [cited by applicant]
US 20200289039A1 · Bullington · 2020 [cited by applicant]
US 20210145336A1 · Rogers · 2021 [cited by applicant]
US 20210275068A1 · Miazga · 2021 [cited by applicant]
US 20220151525A1 · Bullington · 2022 [cited by applicant]
US 20220151527A1 · Bullington · 2022 [cited by applicant]
US 20220160271A1 · Ivosevic · 2022 [cited by applicant]
US 20220304600A1 · Hammer · 2022 [cited by applicant]
US 20220304664A1 · Hammer · 2022 [cited by applicant]
CA 2993646 · 2017 [cited by applicant]
CN 1717280 · 2006 [cited by applicant]
CN 104107054 · 2014 [cited by applicant]
CN 104981203 · 2015 [cited by applicant]
DE 7203008 · 1972 [cited by applicant]
DE 2541494 · 1977 [cited by applicant]
DE 29913417 · 2000 [cited by applicant]
DE 10038026 · 2001 [cited by applicant]
DE 10134913 · 2003 [cited by applicant]
DE 10134913C2 · 2003 [cited by applicant]
DE 10243129 · 2004 [cited by applicant]
EP 0448795 · 1991 [cited by applicant]
EP 0448795A2 · 1991 [cited by applicant]
EP 1665986 · 2006 [cited by applicant]
EP 2593169A1 · 2013 [cited by applicant]
EP 3324845A1 · 2018 [cited by applicant]
EP 3562397A1 · 2019 [cited by applicant]
EP 3622890A1 · 2020 [cited by applicant]
GB 1378602A · 1974 [cited by applicant]
JP S5643474 · 1981 [cited by applicant]
JP S5789869 · 1982 [cited by applicant]
JP S5825146A · 1983 [cited by applicant]
JP S5867238A · 1983 [cited by applicant]
JP H02224742 · 1990 [cited by applicant]
JP H08257018 · 1996 [cited by applicant]
JP H09504726A · 1997 [cited by applicant]
JP 2001000424 · 2001 [cited by applicant]
JP 2005349196 · 2005 [cited by applicant]
JP 2009131273A · 2009 [cited by applicant]
JP 2012016496A · 2012 [cited by applicant]
JP 2013240628 · 2013 [cited by applicant]
JP 5643474 · 2014 [cited by applicant]
JP 5789869B2 · 2015 [cited by applicant]
JP 5825146B2 · 2015 [cited by applicant]
JP 5867238B2 · 2016 [cited by applicant]
JP 2016504075 · 2016 [cited by applicant]
JP 2019534792A · 2019 [cited by applicant]
JP 2020000340A · 2020 [cited by applicant]
JP 6643474B2 · 2020 [cited by applicant]
JP 6734490 · 2020 [cited by applicant]
WO 199216144 · 1992 [cited by applicant]
WO 9605875A1 · 1996 [cited by applicant]
WO 1996005875 · 1996 [cited by applicant]
WO 2007033319A1 · 2007 [cited by applicant]
WO 2008101025 · 2008 [cited by applicant]
WO 2010062734A1 · 2010 [cited by applicant]
WO 2011162772A1 · 2011 [cited by applicant]
WO 2013082301A1 · 2013 [cited by applicant]
WO 2013181352A1 · 2013 [cited by applicant]
WO 2014058945 · 2014 [cited by applicant]
WO 2015150742 · 2015 [cited by applicant]
WO 2017019552A1 · 2017 [cited by applicant]
WO 2018125929A1 · 2018 [cited by applicant]
WO 2019055487A1 · 2019 [cited by applicant]
WO 2019232196A1 · 2019 [cited by applicant]
Office Action (Non-Final Rejection) dated Sep. 24, 2024 for U.S. Appl. No. 18/783,173 ; (pp. 1-62). [cited by applicant]
Office Action (Non-Final Rejection) dated Sep. 17, 2024 for U.S. Appl. No. 17/893,079 ; (pp. 1-50). [cited by applicant]
Office Action (Non-Final Rejection) dated Sep. 23, 2024 for U.S. Appl. No. 17/730,118 ; (pp. 1-73). [cited by applicant]
Office Action (Non-Final Rejection) dated Sep. 17, 2024 for U.S. Appl. No. 18/783,088 ; (pp. 1-60). [cited by applicant]
Office Action (Notice of Deficiencies) dated Oct. 14, 2023 for IL App No. 309380 (pp. 1-7). [cited by applicant]
Office Action (Non-Final Rejection) mailed Nov. 29, 2022 for Application No. 2021-214177, pp. 1-3. [cited by applicant]
Notice of Allowance mailed Jun. 20, 2023; 6 pages. [cited by applicant]
Office Action (Non-Final Rejection) mailed Nov. 4, 2022 for U.S. Appl. No. 17/094,692, pp. 1-50. [cited by applicant]
Notice of Allowance mailed Apr. 20, 2023; 36 pages. [cited by applicant]
Office Action (Non-Final Rejection) mailed Aug. 4, 2022 for U.S. Appl. No. 16/819,033, pp. 1-35. [cited by applicant]
Notice of Allowance mailed Nov. 28, 2022; 9 pages. [cited by applicant]
Notice of Allowance mailed Jul. 4, 2024; 9 pages. [cited by applicant]
Office Action mailed May 21, 2024; 6 pages. [cited by applicant]
European Patent Office, Examination Report for European Patent Application 20781928.5, dated Jul. 31, 2024, pp. 1-6. [cited by applicant]
International Search Report and Written Opinion dated Nov. 5, 2015, for PCT application No. PCT/US2015/035870. 6 pages. [cited by applicant]
International Search Report and Written Opinion dated Jul. 16, 2020 for PCT application No. PCT/US2020/026276. 9 pages. [cited by applicant]
Bullington, et al., Systems and Methods for Sample Collection with Reduced Hemolysis, Exhibit H in U.S. Appl. No. 62/517,681, dated Jun. 9, 2017, 131 pages. [cited by applicant]
International Search Report and Written Opinion dated Jun. 19, 2020, for PCT application No. PCTUS2020/023617. 12 pages. [cited by applicant]
International Search Report/Written Opinion for PCT/US17/68569 dated Apr. 25, 2018. 9 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US16/43709, Dated Oct. 19, 2016. 13 pages. [cited by applicant]
[cited by applicant]
Hillyer, Christopher D., et al. “Bacterial Contamination of Blodd Components: Risks, Strategies and Regulation,” Hematology, 2003, pp. 575-589. [cited by applicant]
De Korte, Dirk, et al. “Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections.” Vox sanguinis 83.1 (2002): 13-16. [cited by applicant]
Brecher, Mark E., et al. “Bacterial contamination of blood components.” Clinical microbiology reviews 18.1 (2005): 195-204. [cited by applicant]
Van Zundert, Adrien. “New closed IV catheter system.” Acta Anæsthesiologica Belgica 56.3 (2005): 283-285. [cited by applicant]
Hall, Keri K., et al. “Updated review of blood culture contamination.” Clinical microbiology reviews 19.4 (2006): 788-802. [cited by applicant]
Li, Yiwen, et al. “Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye Dil.” Nature protocols 3.11 (2008): 1703-1708. [cited by applicant]
Page, Catherine, et al. “Blood conservation devices in critical care: a narrative review.” Annals of intensive care 3 (2013): 1-6. [cited by applicant]
Abbott Point of Care, Cartridge and Test Information, Art: 714258-01O; Rev. Date: Aug. 15, 2016, 1-6 pages. [cited by applicant]
Zimmon, David S. et al. “Effect of portal venous blood flow diversion on portal pressure.” The Journal of Clinical Investigation 65.6 (1980): 1388-1397. [cited by applicant]
Patton, Richard G., et al. “Innovation for reducing blood culture contamination: initial specimen diversion technique.” Journal of clinical microbiology 48.12 (2010): 4501-4503. [cited by applicant]
Tang, Menglin, et al. “Closed blood conservation device for reducing catheter-related infections in children after cardiac surgery.” Critical Care Nurse 34.5 (2014): 53-60. [cited by applicant]
Ernst, Dennis J. et al. “NCCLS simplifies the order of draw: a brief history.” MLO: medical laboratory observer 36.5 (2004): 1-5 pages. [cited by applicant]
Gottlieb, T. “Hazards of bacterial contamination of blood products.” Anaesthesia and intensive care 21.1 (1993): 20-23. [cited by applicant]
Norberg, Alonna, et al. “Contamination rates of blood cultures obtained by dedicated phlebotomy vs intravenous catheter.” Jama 289.6 (2003): 726-729. [cited by applicant]
Quilici, Nathalie, et al. “Differential quantitative blood cultures in the diagnosis of catheter-related sepsis in intensive care units.” Clinical infectious diseases 25.5 (1997): 1066-1070. [cited by applicant]
Napolitano, Marcello, et al. “Quality control of bacterial contamination of blood components: the feasibility of diversion system testing.” Blood Transfus 2 (2004): 231-232. [cited by applicant]
De Korte, Dirk, et al. “Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands.” Transfusion 46.3 (2006): 476-485. [cited by applicant]
Liumbruno, Giancarlo Maria, et al. “Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components.” Blood Transfusion 7.2 (2009): … [cited by applicant]
NCCLS. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard—Fifth Edition. H3-A5, vol. 23, No. 32. Replaces H3-A4; vol. 18, No. 7. 1-52 pages. http://demo.nextlab.ir/Organizatio… [cited by applicant]
Challiner, A., et al. “Venous/arterial blood management protection system.” Anaesthesia 47.2 (1992): 169-169. [cited by applicant]
Murphy, Michael F. “Better Blood Transfusion.” Journal of the Intensive Care Society 4.3 (2003): 78-80. [cited by applicant]
Palavecino, Elizabeth L., et al. “Detecting bacterial contamination in platelet products.” Clinical laboratory 52.9-10 (2006): 443-456. [cited by applicant]
Sheppard, Chelsea A., et al. “Bacterial contamination of platelets for transfusion: recent advances and issues.” Laboratory Medicine 36.12 (2005): 767-770. [cited by applicant]
Shulman, Gerald. “Quality of processed blood for autotransfusion.” Journal of Extracorporeal Technology 32.1 (2000): 11-19. [cited by applicant]
Weinbaum, Fredric I., et al. “Doing it right the first time: quality improvement and the contaminant blood culture.” Journal of Clinical Microbiology 35.3 (1997): 563-565. [cited by applicant]
Weinstein, Melvin P. “Blood culture contamination: persisting problems and partial progress.” Journal of clinical microbiology 41.6 (2003): 2275-2278. [cited by applicant]
Weinstein, Melvin P., et al. “The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults… [cited by applicant]
Weinstein, Melvin P. “Current blood culture methods and systems: clinical concepts, technology, and interpretation of results.” Clinical infectious diseases 23.1 (1996): 40-46. [cited by applicant]
Closed IV, BD Saf-T-Intima. “Catheter System, Becton, Dickinson and Company, Brochure.” Retrieved from the Internet (Aug. 23, 2019). 4 pages. [cited by applicant]
Perez, P., et al. “Multivariate analysis of determinants of bacterial contamination of whole-blood donations.” Vox Sanguinis 82.2 (2002): 55-60. [cited by applicant]
McDonald, Carl P. “Interventions implemented to reduce the risk of transmission of bacteria by transfusion in the English National Blood Service.” Transfusion Medicine and Hemotherapy 38.4 (2011): 255-258. [cited by applicant]
Lifesciences, Edwards. “Conservation. Safety. Simplicity. Edwards VAMP and VAMP Jr. Systems.” (2002). 4 pages. [cited by applicant]
Sheppard, et al., Bacterial Contamination of Platelets for Transfusion: Recent Advances and Issues, Labmedicine, vol. 36, No. 12, Dec. 2005 (“Sheppard 2005”). [cited by applicant]
BD Diagnostics, “Venous Blood Collection, BD Vacutainer Passive Shielding Blood Collection Needle ” literature (2005) 2 pages. [cited by applicant]
Barnard, Dorothy R., et al. “Fibronectin (cold insoluble globulin) in the neonate,” The Journal of Pediatrics, vol. 102, Issue 3, Mar. 1983, pp. 453-455. [cited by applicant]
Mayer, G.A. “A Method for the Reliable Determination of Clotting Time in Whole Blood,” Canadian Medical Association Journal, Jun. 15, 1955, vol. 72, pp. 927-929. [cited by applicant]
Ziegler, R., et al. “Controlled Clinical Laboratory Comparison of Two Supplemented Aerobic and Anaerobic Media Used in Automated Blood Culture Systems to Detect Bloodstream Infections,” Journal of Clinical Microbiology,… [cited by applicant]
Pall Medical, “Leukotrap Filtration Systems for Whole Blood Derived Platelets, Leukotrap RC PL and Leukotrap PL Systems” literature, (2005) 8 pages. [cited by applicant]
Meissner, George F. , et al., “The Standard Clotting Time, A Method Based on the Use of Whole Venous Blood in Capillary Tubes,” The American Journal of Clinical Pathology, vol. 39, No. 3., pp. 321-323, Mar. 1963. [cited by applicant]
U.S. Appl. No. 62/845,767, filed May 9, 2019, Brewer Michael. [cited by applicant]
JP Office Action mailed Feb. 27, 2024; 11 pages. [cited by applicant]
Notice of Allowance mailed Jan. 17, 2024; 16 pages. [cited by applicant]
Office Action (Notice of Section 18) dated Dec. 20, 2023 for IL App No. 309380 (pp. 1-5). [cited by applicant]
Examination Report dated Sep. 28, 2023, for European Patent Application No. 22181212.6. 5 pages. [cited by applicant]
JP Notice of Allowance mailed Jun. 20, 2023; 6 pages. [cited by applicant]
Office Action (Non-Final Rejection) dated Oct. 4, 2023 for U.S. Appl. No. 17/538,990 (pp. 1-47). [cited by applicant]
Notice of Allowance mailed Sep. 14, 2023; 90 pages. [cited by applicant]
Notice of Allowance mailed Sep. 8, 2023; 35 page. [cited by applicant]
Office Action (Final Rejection) dated Aug. 25, 2023 for U.S. Appl. No. 18/113,710 (pp. 1-50). [cited by applicant]
Japanese Patent Office, Notice of Reasons for Rejection for JP Application No. JP 2020-118498 date Aug. 10, 2021. [cited by applicant]
Japanese Patent Office, Notice of Reasons for Rejection dated Jun. 15, 2021, Application No. JP 2019-534792, 6 pages. [cited by applicant]
Japanese Patent Office, Notice of Reasons for Rejection, Japanese patent application No. JP2018-523384, dated Jul. 23, 2019, 5 pages. [cited by applicant]
European Patent Office; Communication pursuant to Article 94(3) EPC, dated Oct. 31, 2018; 11 pages. [cited by applicant]
Examination Report No. 1 dated Apr. 29, 2020, for Australian Patent Application No. 2016297849. 3 pages. [cited by applicant]
European Patent Application No. EP19200766.4 extended European Search Report dated Dec. 2, 2019, 11 pages. [cited by applicant]
European Patent Office, Extended European Search Report for European Patent Application 20197213.0-1132, dated Dec. 9, 2020, 6 pages. [cited by applicant]
Communication Under Rule 71(3) EPC dated Apr. 22, 2020 for EP application No. 17840467.9. 125 pages. [cited by applicant]
Office Action (Non-Final Rejection) dated Jan. 25, 2024 for IL App. 302893 (pp. 1-3). [cited by applicant]
Office Action (Non-Final Rejection) dated Apr. 25, 2023 for U.S. Appl. No. 16/838,017 (pp. 1-20). [cited by applicant]
Office Action (Final Rejection) dated Jan. 29, 2024 for U.S. Appl. No. 16/838,017 (pp. 1-44). [cited by applicant]
“Membrane Definition & Meaning,” Merriam-Webster, Merriam-Webster, Apr. 22, 2009, www.merriam-webster.com/ dictionary/membrane. (Year: 2009). [cited by applicant]
Office Action (Advisory Action) dated Feb. 9, 2024 for U.S. Appl. No. 16/838,017 (pp. 1-6). [cited by applicant]
Office Action (Non-Final Rejection) dated Apr. 16, 2024 for U.S. Appl. No. 16/838,017 (pp. 1-19). [cited by applicant]
Office Action (Non-Final Rejection) dated May 21, 2024 for IL App. 286812 (pp. 1-3). [cited by applicant]
First Office Action (Non-Final Rejection) dated Jan. 16, 2024 for JP App. 2021-558648 (pp. 1-6). [cited by applicant]
First Office Action (Non-Final Rejection) dated Sep. 27, 2023 for CN App. 202080000666.0 (pp. 1-11). [cited by applicant]
Second Office Action (Non-Final Rejection dated Apr. 28, 2024 for CN App. 202080000666.0 (pp. 1-11). [cited by applicant]
European Patent Office, Extended European Search Report for European Patent Application 21818838.1-1122, dated Apr. 22, 2024, 11 pages. [cited by applicant]
European Patent Office, Extended European Search Report for European Patent Application 23155927.9-1122, dated Jul. 26, 2023, pp. 1-8. [cited by applicant]
Office Action (Non-Final Rejection) mailed Oct. 4, 2023 for U.S. Appl. No. 17/538,900 (1-47). [cited by applicant]
First Office Action (Non-Final Rejection) dated Aug. 3, 2023 for CN Application No. 202010300942.7. 21 pages. [cited by applicant]
Office Action (Non-Final Rejection) dated Feb. 21, 2023 for U.S. Appl. No. 17/893,079, pp. 1-32. [cited by applicant]
Office Action (Final Rejection) dated Jul. 19, 2023 for U.S. Appl. No. 17/893,079, pp. 1-21. [cited by applicant]
Advisory Action dated Sep. 29, 2023 for U.S. Appl. No. 17/893,079, pp. 1-24. [cited by applicant]
European Patent Office, Extended European Search Report for European Patent Application 20781928.5-1122 dated Oct. 28, 2022, pp. 1-10. [cited by applicant]
Rule 70(a) Communication for European Application No. 20781928.5-1122 dated Nov. 15, 2022, 1 page. [cited by applicant]
International Search Report and Written Opinion dated Mar. 19, 2020 for PCT application No. PCT/US2020/023617. pages. [cited by applicant]
International Search Report and Written Opinion dated Sep. 28, 2021 for PCT application No. PCT/US2021/035294. 7 pages. [cited by applicant]
European Patent Office, Extended European Search Report for European Patent Application 22181212.6-1122 dated Oct. 24, 2022, pp. 1-10. [cited by applicant]
Australian Patent Office, Australian Examination Report No. 1 for Application No. 2021120 622 dated Mar. 18, 2022, 3 pages. [cited by applicant]
Notice of Allowance mailed Mar. 1, 2023; 3 pages. [cited by applicant]
First Office Action dated Nov. 24, 2021 for IL Application No. 286030, pp. 1-3. [cited by applicant]
Notice of Allowance mailed Jan. 29, 2023; 87 pages. [cited by applicant]
Office Action (Non-Final Rejection) dated Aug. 10, 2021 for Japanese Application No. 2020-118498, pp. 1-7. [cited by applicant]
Office Action (Non-Final Rejection) dated Mar. 28, 2022 for Japanese Application No. 2020-118498, pp. 1-3. [cited by applicant]
Office Action (Non-Final Rejection) dated Sep. 1, 2022 for Japanese Application No. 2020-118498, pp. 1-4. [cited by applicant]
Notice of Allowance mailed Apr. 4, 2023; 6 pages. [cited by applicant]
Rule 71(3) Communication and Text for Grant mailed Aug. 31, 2022 for European Application No. 19200766.4-1122. 189 pages. [cited by applicant]
Office Action (Non-Final Rejection) mailed Jan. 21, 2022 for Israeli Application No. 267684. 3 pages. [cited by applicant]
Notice of Allowance mailed Feb. 14, 2023; 122 pages. [cited by applicant]